Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2020

01-04-2020 | Original Article

A Single Nucleotide Polymorphism in GAS5 lncRNA is Associated with Risk of Bladder Cancer in Iranian Population

Authors: Azadeh Rakhshan, Mohammad Hossein Esmaeili, Mir Salar Kahaei, Mohammad Taheri, Mir Davood Omrani, Rezvan Noroozi, Soudeh Ghafouri-Fard

Published in: Pathology & Oncology Research | Issue 2/2020

Login to get access

Abstract

Down-regulation of the long non-coding RNA (lncRNA) growth arrest-specific 5 (GAS5) has a pathogenic role in bladder cancer. Moreover, genomic variants of this lncRNA have been associated with risk of diverse cancers. In the present project, we genotyped two putative functional SNPs (rs2067079 and rs6790) in 122 bladder cancer patients and 150 age- and sex-matched healthy subjects. The rs2067079 was associated risk of bladder cancer in recessive inheritance model (TT vs.CC + CT: OR (95% Confidence interval (CI)) = 2.67 (1.27–5.62), adjusted P value = 0.02). The T G haplotype (rs2067079 and rs6790) increased the risk of bladder cancer in the assessed population (OR (95% CI) = 1.73 (1.18–2.56), adjusted P value = 0.02). Consequently, in the current project we introduced a novel risk locus for bladder cancer in Iranian population.
Literature
1.
Rafiemanesh H, Lotfi Z, Bakhtazad S, Ghoncheh M, Salehiniya H (2018) The epidemiological and histological trend of bladder cancer in Iran. J Cancer Res Ther 14(3):532–536CrossRef
2.
Gu J, Wu XF (2011) Genetic susceptibility to bladder cancer risk and outcome. Pers Med 8(3):365–374CrossRef
3.
Taheri M, Omrani MD, Ghafouri-Fard S (2018) Long non-coding RNA expression in bladder cancer. Biophys Rev 10(4):1205–1213CrossRef
4.
Minotti L, Agnoletto C, Baldassari F, Corra F, Volinia S (2018) SNPs and somatic mutation on long non-coding RNA: new frontier in the cancer studies? High-throughput. 7(4)CrossRef
5.
Zhang H, Guo Y, Song Y, Shang C (2017) Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma. Cancer Chemother Pharmacol 79(1):49–55CrossRef
6.
Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT (2009) GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene. 28(2):195–208CrossRef
7.
Mahdi Eftekharian M, Noroozi R, Komaki A, Mazdeh M, Taheri M, Ghafouri-Fard S (2019) GAS5 genomic variants and risk of multiple sclerosis. Neurosci Lett 701:54–57CrossRef
8.
Smith CM, Steitz JA (1998) Classification of gas5 as a multi-small-nucleolar-RNA (snoRNA) host gene and a member of the 5′-terminal oligopyrimidine gene family reveals common features of snoRNA host genes. Mol Cell Biol 18(12):6897–6909CrossRef
9.
Ghaforui-Fard S, Taheri M (2019) Growth arrest specific transcript 5 in tumorigenesis process: An update on the expression pattern and genomic variants. Biomed Pharmacother 112
10.
Li QJ, Ma G, Sun SH, Xu Y, Wang BJ (2018) Polymorphism in the promoter region of lncRNA GAS5 is functionally associated with the risk of gastric cancer. Clin Res Hepatol Gas 42(5):478–482CrossRef
11.
Li WH, Huang K, Wen FB, Cui GH, Guo HZ, Zhao S (2017) Genetic variation of lncRNA GAS5 contributes to the development of lung cancer. Oncotarget. 8(53):91025–91029CrossRef
12.
Zhu ZS, Xue YZ, Fu W, Li CY, Feng LJ, Xing YH et al (2016) Functional indel polymorphism within lncRNA GAS5 and colorectal carcinoma risk. Int J Clin Exp Pathol 9(11):11767–11773
13.
Guo Z, Wang YH, Zhao Y, Jin Y, An L, Wu B et al (2017) Genetic polymorphisms of long non-coding RNA GAS5 predict platinum-based concurrent chemoradiotherapy response in nasopharyngeal carcinoma patients. Oncotarget. 8(37):62286–62297CrossRef
14.
Wang M, Guo C, Wang L, Luo G, Huang C, Li YW et al (2018) Long noncoding RNA GAS5 promotes bladder cancer cells apoptosis through inhibiting EZH2 transcription. Cell Death Dis 9
15.
Yoo J, Lee Y, Kim Y, Rha SY, Kim Y (2008) SNPAnalyzer 2.0: a web-based integrated workbench for linkage disequilibrium analysis and association analysis. BMC Bioinf 9:290CrossRef
16.
Liu ZH, Wang W, Jiang JT, Bao ED, Xu DL, Zeng YG et al (2013) Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6. PLoS One 8(9)CrossRef
17.
Ren C, An GL, Zhao CH, Ouyang ZY, Bo XC, Shu WJ (2018) Lnc2Catlas: an atlas of long noncoding RNAs associated with risk of cancers. Sci Rep-Uk 8
18.
Ward LD, Kellis M (2012) HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 40(D1):D930–D9D4CrossRef
19.
Zhang Q, Stovall DB, Inoue K, Sui G (2011) The oncogenic role of Yin Yang 1. Crit Rev Oncog 16(3–4):163–197CrossRef
20.
Zaravinos A, Lambrou GI, Boulalas I, Delakas D, Spandidos DA (2011) Identification of common differentially expressed genes in urinary bladder cancer. PLoS One 6(4):e18135CrossRef
Metadata
Title
A Single Nucleotide Polymorphism in GAS5 lncRNA is Associated with Risk of Bladder Cancer in Iranian Population
Authors
Azadeh Rakhshan
Mohammad Hossein Esmaeili
Mir Salar Kahaei
Mohammad Taheri
Mir Davood Omrani
Rezvan Noroozi
Soudeh Ghafouri-Fard
Publication date
01-04-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00693-2

Other articles of this Issue 2/2020

Pathology & Oncology Research 2/2020 Go to the issue

Original Article

All Benign and Malignant Apocrine Breast Lesions Over-Express Claudin 1 and 3 and Are Negative for Claudin 4

Original Article

Inhibitory Effect of (2R)-1-(1-Benzofuran-2-yl)-N-propylpentan-2-amine on Lung Adenocarcinoma

Original Article

YAP1 Is Involved in Tumorigenic Properties of Prostate Cancer Cells

Original Article

Upregulation of RUNX1 Suppresses Proliferation and Migration through Repressing VEGFA Expression in Hepatocellular Carcinoma

Original Article

Peptidyl Arginine Deiminase, Type II (PADI2) Is Involved in Urothelial Bladder Cancer

Original Article

The Haphazard Pattern in Grade-3 Endometrioid Carcinoma Is Associated with Poor Prognosis and Tumor Lymphocyte Infiltration
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits